Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Danielle Brazel, Gianna Kroening, Misako Nagasaka
BioDrugs (2022) Vol. 36, Iss. 6, pp. 717-729
Open Access | Times Cited: 18

Showing 18 citing articles:

Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Yeji Hong, Su-Min Nam, Aree Moon
Archives of Pharmacal Research (2023) Vol. 46, Iss. 3, pp. 131-148
Closed Access | Times Cited: 40
A review on non-small cell lung cancer
Sunil Kumar Verma, Minakshi Pandey, R. P. Khare, et al.
Vacunas (2024) Vol. 25, Iss. 2, pp. 239-253
Closed Access | Times Cited: 6
Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
Chiara Reina, Berina Šabanović, Chiara Lazzari, et al.
Translational research (2024) Vol. 272, pp. 41-53
Closed Access | Times Cited: 5
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy
Yue Shen, Jie-Qi Chen, Xiangping Li
Genes & Diseases (2024) Vol. 12, Iss. 3, pp. 101374-101374
Open Access | Times Cited: 4
Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance
Zuyue Liao, Cheng Luo, Yidie Huang, et al.
Expert Opinion on Drug Safety (2025), pp. 1-10
Closed Access
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
Edanur Topalan, Ahmet Büyükgüngör, Melih Çiğdem, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 4
Open Access
Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review
Ionas Papassotiriou, Antonios Kapogiannatos, C. Makatsoris, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5489-5489
Open Access | Times Cited: 3
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report
Xiaoqing Huang, Lixin Zhou, Jiadong Xia, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Yating Hou, Xingyang Xue, Zhuoyun Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Efficacy and safety outcomes of emerging EGFR‑TKIs for patients with non‑small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta‑analysis
Kang Xie, Jing Wang, Juan Jiang, et al.
Oncology Letters (2025) Vol. 29, Iss. 6, pp. 1-13
Open Access
Discovery of Novel 5,6-Dihydro-4H-pyrido[2,3,4-de]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases
Leifu Yang, Yaxin Li, Yunling Du, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5662-5682
Closed Access | Times Cited: 2
A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer
Song Hu, Hao Ming, Qian He, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data
Yalan Tong, Xiang‐Bo Wan, Chang Yin, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway
Yiping Wang, Baolan Wang, Liqun Zhou, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 12, pp. 5680-5696
Closed Access | Times Cited: 1
[Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].

PubMed (2023) Vol. 26, Iss. 5, pp. 325-337
Closed Access | Times Cited: 2
A review on non-small cell lung cancer
Sunil Kumar Verma, Minakshi Pandey, R. P. Khare, et al.
Vacunas (English Edition) (2024) Vol. 25, Iss. 2, pp. 239-253
Closed Access
Proximal Femoral Metastasis From Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Mimicking Osteosarcoma on Magnetic Resonance Imaging
Changjun Chen, Jun Yin, Hao Xuan Zhang, et al.
World Journal of Oncology (2024) Vol. 15, Iss. 4, pp. 731-735
Open Access
Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review
Ning Yi Yap, Komathi Perumal, Pathmanathan Rajadurai
ecancermedicalscience (2024) Vol. 18
Open Access
Page 1

Scroll to top